Checkmate Pharmaceuticals Inc logo

CMPI - Checkmate Pharmaceuticals Inc Share Price

$11.59 -0.2  -1.4%

Last Trade - 27/11/20

Sector
Healthcare
Size
Small Cap
Market Cap £177.5m
Enterprise Value £117.3m
Revenue £n/a
Position in Universe 3736th / 6429
Bullish
Bearish
Unlock CMPI Revenue
Momentum
Relative Strength (%)
1m -10.9%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -33.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Checkmate Pharmaceuticals Inc revenues was not reported.Net loss applicable to common stockholders totaled to $32M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CMPI Revenue Unlock CMPI Revenue

Net Income

CMPI Net Income Unlock CMPI Revenue

Normalised EPS

CMPI Normalised EPS Unlock CMPI Revenue

PE Ratio Range

CMPI PE Ratio Range Unlock CMPI Revenue

Dividend Yield Range

CMPI Dividend Yield Range Unlock CMPI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CMPI EPS Forecasts Unlock CMPI Revenue
Profile Summary

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing its technology to harness the power of the immune system to combat cancer. Its product candidate, CMP-001, is a differentiated Toll-like receptor 9 (TLR9), agonist delivered as a biologic virus-like particle (VLP), utilizing a CpG-A oligonucleotide as a key component. When injected into a tumor, CMP-001 is designed to trigger the body’s innate immune system, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack both the injected tumor and also tumors throughout the body. The Company is also developing CMP-001 in combination with several checkpoint inhibitor immunotherapies in melanoma and head and neck cancer.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated July 15, 2015
No. of Shareholders: n/a
No. of Employees: 22
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 21,546,591
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CMPI Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CMPI
Upcoming Events for CMPI
Frequently Asked Questions for Checkmate Pharmaceuticals Inc
What is the Checkmate Pharmaceuticals Inc share price?

As of 27/11/20, shares in Checkmate Pharmaceuticals Inc are trading at $11.59, giving the company a market capitalisation of £177.5m. This share price information is delayed by 15 minutes.

How has the Checkmate Pharmaceuticals Inc share price performed this year?

Shares in Checkmate Pharmaceuticals Inc are currently trading at $11.59 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Checkmate Pharmaceuticals Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Checkmate Pharmaceuticals Inc?

There are no analysts currently covering Checkmate Pharmaceuticals Inc.

When will Checkmate Pharmaceuticals Inc next release its financial results?

Checkmate Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Checkmate Pharmaceuticals Inc dividend yield?

Checkmate Pharmaceuticals Inc does not currently pay a dividend.

Does Checkmate Pharmaceuticals Inc pay a dividend?

Checkmate Pharmaceuticals Inc does not currently pay a dividend.

When does Checkmate Pharmaceuticals Inc next pay dividends?

Checkmate Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Checkmate Pharmaceuticals Inc shares?

To buy shares in Checkmate Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Checkmate Pharmaceuticals Inc?

Shares in Checkmate Pharmaceuticals Inc are currently trading at $11.59, giving the company a market capitalisation of £177.5m.

Where are Checkmate Pharmaceuticals Inc shares listed? Where are Checkmate Pharmaceuticals Inc shares listed?

Here are the trading details for Checkmate Pharmaceuticals Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: CMPI
What kind of share is Checkmate Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Checkmate Pharmaceuticals Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Checkmate Pharmaceuticals Inc share price forecast 2020?

Shares in Checkmate Pharmaceuticals Inc are currently priced at $11.59. At that level they are trading at 0.132% discount to the analyst consensus target price of 0.00.

Analysts covering Checkmate Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.617 for the next financial year.

How can I tell whether the Checkmate Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Checkmate Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $11.59, shares in Checkmate Pharmaceuticals Inc are trading at -9.89% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Checkmate Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Checkmate Pharmaceuticals Inc.

Who are the key directors of Checkmate Pharmaceuticals Inc?

Checkmate Pharmaceuticals Inc's management team is headed by:

Mike Powell - CHM
Arthur Krieg - FDR
Barry Labinger - PRE
Jonathan Lieber - CFO
Who are the major shareholders of Checkmate Pharmaceuticals Inc?

Here are the top five shareholders of Checkmate Pharmaceuticals Inc based on the size of their shareholding:

VenBio Partners LLC Private Equity
Percentage owned: 17.05% (3.67m shares)
Sofinnova Investments, Inc Venture Capital
Percentage owned: 16.74% (3.61m shares)
Novo Holdings A/S Venture Capital
Percentage owned: 10.07% (2.17m shares)
Longitude Capital Management Co., LLC Venture Capital
Percentage owned: 8.33% (1.79m shares)
Medicxi Ventures (UK) LLP Venture Capital
Percentage owned: 6.97% (1.50m shares)
Similar to CMPI
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.